Puhong Zhang1, Jialin Gao2, Chun Pu3, Gang Feng3, Lizhuo Wang4, Lizhu Huang3, Yao Zhang5. 1. Anhui Province Key Laboratory of Biological Macro-molecules Research, Wannan Medical College, China; Department of Clinical Laboratory, The Second Affiliated Hospital of Wannan Medical College, China. 2. Department of Endocrinology and Genetic Metabolism, Yijishan Hospital of Wannan Medical College, China; Anhui Province Key Laboratory of Biological Macro-molecules Research, Wannan Medical College, China. 3. Department of Clinical Laboratory, Yijishan Hospital of Wannan Medical College, China. 4. Department of Biochemistry and Molecular Biology, Wannan Medical College, China; Anhui Province Key Laboratory of Biological Macro-molecules Research, Wannan Medical College, China. 5. Department of Biochemistry and Molecular Biology, Wannan Medical College, China; Anhui Province Key Laboratory of Biological Macro-molecules Research, Wannan Medical College, China. Electronic address: yaozhang_wnmc@yahoo.com.
Abstract
BACKGROUND: Apolipoprotein M (apoM) concentrations were decreased in type 2 diabetes mellitus (T2DM). ApoM was selectively expressed in renal tubular epithelial cells. We investigated the changes in plasma apoM concentrations in diabetic nephropathy (DN) patients and the potential of apoM as a biomarker of DN. METHODS: A total of 96 DN patients and 100 age- and sex-matched diabetic non-nephropathy (non-DN) patients and 110 healthy controls were included. All T2DM patients were divided into 3 groups according to urinary albumin excretion: normoalbuminuria (n=100), microalbuminuria (n=50) and macroalbuminuria (n=46). Plasma apoM concentrations were measured by enzyme-linked immunosorbent assay. RESULTS: DN Patients had higher plasma apoM concentrations than those in non-DN patients (22.23±11.69 vs. 18.96±7.85ng/μl, P<0.05). In addition, microalbuminuria group showed higher plasma apoM concentrations than those in normoalbuminuria group (22.67±11.40 vs. 18.96±7.85ng/μl, P<0.05). The areas under curve (AUC) of apoM using a receiver-operating characteristic (ROC) curve analysis showed that plasma apoM concentrations were not indicators for identification of DN from healthy people (AUC=0.478, P=0.585) and from T2DM (AUC=0.563, P=0.125). DN patients had higher ratios of apoM/HDL-C and apoM/apoA1 than those in healthy controls and in non-DN patients. ApoM/HDL-C and apoM/apoA1 ratios could be used as indicators for identification of DN from healthy people (AUC=0.597, P=0.016; AUC=0.665, P=0.000, respectively) and from T2DM (AUC=0.580, P=0.050; AUC=0.601, P=0.015, respectively). CONCLUSIONS: ApoM/HDL-C and apoM/apoA1 ratios could be used as indicators for identification of DN from healthy people and from T2DM patients.
BACKGROUND:Apolipoprotein M (apoM) concentrations were decreased in type 2 diabetes mellitus (T2DM). ApoM was selectively expressed in renal tubular epithelial cells. We investigated the changes in plasma apoM concentrations in diabetic nephropathy (DN) patients and the potential of apoM as a biomarker of DN. METHODS: A total of 96 DN patients and 100 age- and sex-matched diabetic non-nephropathy (non-DN) patients and 110 healthy controls were included. All T2DM patients were divided into 3 groups according to urinary albumin excretion: normoalbuminuria (n=100), microalbuminuria (n=50) and macroalbuminuria (n=46). Plasma apoM concentrations were measured by enzyme-linked immunosorbent assay. RESULTS: DN Patients had higher plasma apoM concentrations than those in non-DN patients (22.23±11.69 vs. 18.96±7.85ng/μl, P<0.05). In addition, microalbuminuria group showed higher plasma apoM concentrations than those in normoalbuminuria group (22.67±11.40 vs. 18.96±7.85ng/μl, P<0.05). The areas under curve (AUC) of apoM using a receiver-operating characteristic (ROC) curve analysis showed that plasma apoM concentrations were not indicators for identification of DN from healthy people (AUC=0.478, P=0.585) and from T2DM (AUC=0.563, P=0.125). DN patients had higher ratios of apoM/HDL-C and apoM/apoA1 than those in healthy controls and in non-DN patients. ApoM/HDL-C and apoM/apoA1 ratios could be used as indicators for identification of DN from healthy people (AUC=0.597, P=0.016; AUC=0.665, P=0.000, respectively) and from T2DM (AUC=0.580, P=0.050; AUC=0.601, P=0.015, respectively). CONCLUSIONS:ApoM/HDL-C and apoM/apoA1 ratios could be used as indicators for identification of DN from healthy people and from T2DM patients.
Authors: Nathaniel L Baker; Samar M Hammad; Kelly J Hunt; Andrea Semler; Richard L Klein; Maria F Lopes-Virella Journal: Diabetes Date: 2022-08-01 Impact factor: 9.337
Authors: Edward B Neufeld; Masaki Sato; Scott M Gordon; Vinay Durbhakula; Nicolas Francone; Angel Aponte; Gizem Yilmaz; Denis Sviridov; Maureen Sampson; Jingrong Tang; Milton Pryor; Alan T Remaley Journal: Biology (Basel) Date: 2019-07-12
Authors: Arthur T Kopylov; Anna L Kaysheva; Olga Papysheva; Iveta Gribova; Galina Kotaysch; Lubov Kharitonova; Tatiana Mayatskaya; Anna Krasheninnikova; Sergey G Morozov Journal: Cells Date: 2020-04-21 Impact factor: 6.600